Status
Conditions
About
We are conducting this study to develop a disease-specific instrument, a quality of life instrument and a comprehensive list of costs associated with overweight and obesity.
Full description
Despite evidence on the burden of BMI >25, few disease-specific instruments comprehensively capture its multidimensional impact. Existing frameworks often target obesity (BMI ≥30) or patients on pharmacological or surgical therapy. Overweight and extremely obese populations are underrepresented, and economic and psychosocial dimensions are rarely integrated into severity staging.
This study, therefore, aims to systematically evaluate symptoms, comorbidities, HRQoL, and costs across the full spectrum of individuals with BMI >25, excluding those on GLP-1 therapy. Integrating clinician and patient perspectives will support the development of more inclusive severity measures and inform early intervention strategies.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
Patient group
Healthcare professional participant must meet the following criteria for inclusion in the study:
HCP is aged ≥18 years at the time of survey completion.
HCP is suitably qualified and involved in the healthcare management of patients with a BMI over 25
HCP is willing to participate in all study activities.
HCP is able to read, write, and converse in English.
Exclusion Criteria:
A participant who meets any of the following criteria will be excluded from the study:
Loading...
Central trial contact
Omolade Allen, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal